Biotech sector intensifies competition for AATD therapeutic market dominance

Biotechnology firms are aggressively pursuing treatments for alpha-1 antitrypsin deficiency, leading to increased litigation, intellectual property disputes, and geopolitical friction between U.S. and Chinese entities. The surge in activity marks a shift from historical neglect to a high-stakes commercial race, though the clinical efficacy of competing pipelines remains to be proven.